ClinicalTrials.gov
ClinicalTrials.gov Menu

UVA1 Phototherapy in Acral Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03378011
Recruitment Status : Completed
First Posted : December 19, 2017
Last Update Posted : December 19, 2017
Sponsor:
Information provided by (Responsible Party):
Maha Fathy Elmasry, Cairo University

Brief Summary:
evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.

Condition or disease Intervention/treatment Phase
Acral Vitiligo Other: phototherapy Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo
Actual Study Start Date : November 2015
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo

Arm Intervention/treatment
Active Comparator: UVA1 phototherapy
UVA1 phototherapy in acral vitiligo
Other: phototherapy
phototherapy either UVA1 or topical PUVA on acral vitiligo

Active Comparator: Topical PUVA
Topical PUVA in acral vitiligo
Other: phototherapy
phototherapy either UVA1 or topical PUVA on acral vitiligo




Primary Outcome Measures :
  1. effect of medium dose UVA1 phototherapy in treatment of acral vitiligo [ Time Frame: 1 year ]
    effect of medium dose UVA1 phototherapy in treatment of acral vitiligo using point counting and vitiligo area severity index (VASI) score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with acral vitiligo.
  • Patients more than 12 years old.

Exclusion Criteria:

  • Patients less than 12 years old.
  • Patients with any other skin diseases or autoimmune diseases.
  • Patients taking medical treatment or phototherapy for vitiligo.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03378011


Locations
Egypt
Maha Fathy Elmasry
Cairo, Egypt
Sponsors and Collaborators
Cairo University
Investigators
Principal Investigator: Maha Elmasry Cairo University

Responsible Party: Maha Fathy Elmasry, principal investigator, Cairo University
ClinicalTrials.gov Identifier: NCT03378011     History of Changes
Other Study ID Numbers: Dermatology 3
First Posted: December 19, 2017    Key Record Dates
Last Update Posted: December 19, 2017
Last Verified: December 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases